Prevnar 13 Vaccine Description
Prevnar 13 is a sterile suspension of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 protein. Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine.
Prevnar 13 Vaccine Indication
Prevnar 13 is a vaccine indicated in children 6 weeks through 17 years (prior to the 18th birthday) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. For children 6 weeks through 5 years of age (prior to the 6th birthday) for the prevention of otitis media caused by 7 of the 13 serotypes in the vaccine.
In adults 18 years of age and older, Prevnar 13 is indicated for active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes in the vaccine, with certain health conditions.
The CDC’s Advisory Committee on Immunization Practices (ACIP) suggests that adults aged 65 years or older should receive only the 23-valent pneumococcal polysaccharide vaccine (PPSV23) with a few exceptions. This ACIP announcement was issued on November 22, 2019, because the pneumococcal vaccination recommendations had undergone several changes, causing confusion for those who need to select a preventive vaccine.
In 2014, the ACIP recommended that older adults receive the 13-valent pneumococcal conjugate vaccine (PCV13) first, then the PPSV23 at least 1 year later. Since then, widespread childhood vaccination with PCV13 and its predecessor the 7-valent pneumococcal conjugate vaccine have “led to sharp declines in pneumococcal disease among unvaccinated children and adults,” according to the ACIP’s review of the evidence.
Based on that review, the ACIP voted to remove the recommendation for routine use of PCV13, followed by PPSV23 in this senior population.
“Incidence of PCV13-type disease has been reduced to historically low levels among adults aged ≥65 years through indirect effects from pediatric PCV13 use,” the authors wrote.
The PPSV23 vaccine contains 12 serotypes in common with PCV13 and an additional 11 serotypes, for which there are no indirect effects from PCV13 use in children.
But, adults aged 19 years or older with an immunocompromising condition, cerebral spinal fluid leak, or cochlear implant should continue to receive both vaccines, the ACIP recommends.
And, some adults aged 65 years or older may have a greater risk of exposure to strains of Streptococcus pneumoniae covered by the PCV13 vaccine, such as those seniors living in nursing homes or long-term care facilities, people living in areas with low rates of pediatric vaccination with PCV13, or those traveling to areas with no childhood PCV13 vaccination program.
Prevnar 13 Vaccine Dosage
Prevnar 13 is administered as an intramuscular injection only.
Vaccination Schedule - CDC
Prevnar 13 News
- November 27, 2019 – Pneumococcal vaccination recommendations have undergone several changes in recent years, causing confusion for those who need to select a preventive vaccine.
- October 15, 2019 – A new study has found a bacterial infection that can lead to pneumonia or meningitis is linked to weakened immune systems in children.
- September 9, 2019 – Pfizer announced positive preliminary results of a Proof-of-Concept Phase 2 clinical study assessing the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077.
Prevnar 13 vaccine news is published by Precision Vaccinations.com.